Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Contrave (naltrexone/bupropion) in obesity with lifestyle modification (COR-BMOD)
NCT00456521Phase 3Completed
- Sponsor
- Orexigen Therapeutics
- Start
- Mar 2007
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of naltrexone and bupropion in obesity (2 arms), sponsored by Orexigen Therapeutics. Primary endpoints: Body Weight - Mean Percent Change at 56 weeks and Proportion of Subjects With ≥5% Decrease in Body Weight at 56 weeks. Started Mar 2007; status: completed.
02
Drugs
naltrexonebupropion
03
Conditions
obesity
Beyond the preview
Go deeper on NCT00456521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00456521.